Profil
Gur A. Roshwalb is currently a Director at KAHR Medical Ltd., Biosplice Therapeutics, Inc., MiNA Therapeutics Ltd., Viracta Subsidiary, Inc., and Altrubio, Inc. He previously served as the Chief Executive Officer of Celsus Therapeutics Plc from 2013 to 2015.
He was also the President & Chief Executive Officer of Zywie LLC.
From 2013 to 2017, he held the position of Chief Executive Officer & Director at Akari Therapeutics Plc.
Additionally, he has worked as a Director at Sunesis Pharmaceuticals, Inc. and as an Independent Director at Viracta Therapeutics, Inc. from 2021 to 2022.
He has also held positions as Vice President at Venrock Associates and as a Senior Research Analyst at Piper Sandler & Co. (Broker).
He started his career as the Chief Resident at The Mount Sinai Medical Center, Inc. in 1997.
Dr. Roshwalb holds an undergraduate degree from The Trustees of Columbia University in The City of New York, a doctorate from Albert Einstein College of Medicine, Inc., and an MBA from The Leonard N Stern School of Business.
Postes actifs de Gur Roshwalb
| Sociétés | Poste | Début |
|---|---|---|
MiNA Therapeutics Ltd.
MiNA Therapeutics Ltd. BiotechnologyHealth Technology Develops biological and medical products | Directeur/Membre du Conseil | 01/08/2020 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Develops proprietary viral gene activation therapy to address cancers associated with the epstein-barr virus | Directeur/Membre du Conseil | 01/11/2020 |
Altrubio, Inc.
Altrubio, Inc. Pharmaceuticals: MajorHealth Technology Develops immunomodulators to target diseases of the immune system | Directeur/Membre du Conseil | 01/12/2020 |
KAHR Medical Ltd.
KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology Develops immunotherapeutic drugs | Directeur/Membre du Conseil | 01/01/2021 |
Biosplice Therapeutics, Inc.
Biosplice Therapeutics, Inc. BiotechnologyHealth Technology Operates as a pre-clinical research company that develops small-molecule therapeutics for osteoarthritis & cancer | Directeur/Membre du Conseil | 01/04/2021 |
Anciens postes connus de Gur Roshwalb
| Sociétés | Poste | Fin |
|---|---|---|
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures invests in companies located in Israel. The firm focuses on life-sciences, biopharma, digital health and medical technology companies. It provides financing for early and late stage capital requirements with an investment size of USD 10 - 30 million. The firm makes follow-on investments and also acts as lead investor. | Private Equity Investor | 01/07/2024 |
| VIRACTA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 08/06/2022 |
| AKARI THERAPEUTICS, PLC | Directeur Général | 29/05/2017 |
Piper Sandler & Co. (Broker)
Piper Sandler & Co. (Broker) Investment Banks/BrokersFinance Provides brokerage services | Analyst-Equity | 30/11/2007 |
| ░░░ ░░░░░ ░░░░░ ░░░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Gur Roshwalb
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 17 |
|---|---|
Venrock Associates
Venrock Associates Investment ManagersFinance Venrock Associates invests in companies located in the US. The firm focuses on sectors such as intelligent enterprise & AI, security & infrastructure, fintech, healthcare IT, defense & Aerospace, robotics & autonomy and consumer sectors. It participates in early and later stage transactions. | Finance |
Piper Sandler & Co. (Broker)
Piper Sandler & Co. (Broker) Investment Banks/BrokersFinance Provides brokerage services | Finance |
Sunesis Pharmaceuticals, Inc.
Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops oncology therapeutics for treatment of solid and hematologic cancers | Health Technology |
Celsus Therapeutics Plc
Celsus Therapeutics Plc Pharmaceuticals: MajorHealth Technology Develops novel non steroidal anti-inflammatory drugs | Health Technology |
The Trustees of Columbia University in The City of New York
The Trustees of Columbia University in The City of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
KAHR Medical Ltd.
KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology Develops immunotherapeutic drugs | Health Technology |
Albert Einstein College of Medicine, Inc.
Albert Einstein College of Medicine, Inc. Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Leonard N Stern School of Business
The Leonard N Stern School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Biosplice Therapeutics, Inc.
Biosplice Therapeutics, Inc. BiotechnologyHealth Technology Operates as a pre-clinical research company that develops small-molecule therapeutics for osteoarthritis & cancer | Health Technology |
Zywie LLC
Zywie LLC Pharmaceuticals: MajorHealth Technology Operates as a therapeutics company that focuses on the treatment of metabolic and neurodegenerative disorders | Health Technology |
MiNA Therapeutics Ltd.
MiNA Therapeutics Ltd. BiotechnologyHealth Technology Develops biological and medical products | Health Technology |
The Mount Sinai Medical Center, Inc.
The Mount Sinai Medical Center, Inc. Hospital/Nursing ManagementHealth Services Operates charitable teaching hospitals | Health Services |
Akari Therapeutics Plc
Akari Therapeutics Plc BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops therapies for autoimmune and inflammatory diseases | Health Technology |
aMoon Ventures Y Sh Ltd.
aMoon Ventures Y Sh Ltd. Investment ManagersFinance aMoon Ventures invests in companies located in Israel. The firm focuses on life-sciences, biopharma, digital health and medical technology companies. It provides financing for early and late stage capital requirements with an investment size of USD 10 - 30 million. The firm makes follow-on investments and also acts as lead investor. | Finance |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Develops proprietary viral gene activation therapy to address cancers associated with the epstein-barr virus | Health Technology |
Altrubio, Inc.
Altrubio, Inc. Pharmaceuticals: MajorHealth Technology Develops immunomodulators to target diseases of the immune system | Health Technology |
Viracta Therapeutics, Inc.
Viracta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for virus-associated cancers | Health Technology |
















